AJMC highlights fixed-duration AV in CLL

AJMC published an interview on May 21 in which Adam Kittai, MD, described fixed-duration acalabrutinib plus venetoclax as an important new option in frontline chronic lymphocytic leukemia, while stressing that the regimen’s limits should shape how doctors use it. The combination became the first FDA-approved all-oral fixed-duration regimen for previously untreated CLL or small lymphocytic lymphoma in February, based on the phase 3 AMPLIFY trial. Kittai’s argument was not that the regimen has settled the frontline debate, but that it has widened it. The choice now turns less on whether a targeted regimen works at all and more on which patients can accept a time-limited approach, what toxicities they face, and how much uncertainty remains after treatment stops. ### Why is this combination drawing attention now? The FDA approved acalabrutinib with venetoclax on February 20 for adults with previously untreated CLL or SLL. The agency said the approval was based on AMPLIFY, a randomized multicenter trial comparing fixed-duration acalabrutinib plus venetoclax with investigator’s choice of chemoimmunotherapy. The approval gave clinicians an all-oral regimen that is designed to stop after a defined course rather than continue indefinitely. (ajmc.com) AJMC’s May 21 interview with Kittai framed that time-limited structure as part of the appeal. In an earlier AJMC interview published in April, Kittai said the regimen offered the first FDA-approved all-oral fixed-duration CLL option and pointed to improved outcomes versus chemoimmunotherapy. ### What did Kittai say makes it “compelling”? Kittai told AJMC that fixed-duration acalabrutinib plus venetoclax is a compelling option for selected patients. (fda.gov) The attraction is straightforward: patients can receive a targeted, chemotherapy-free regimen and then come off therapy, avoiding the open-ended treatment course that often comes with BTK inhibitor monotherapy. (ajmc.com) The AMPLIFY data also helped support that case. FDA materials say efficacy was evaluated in previously untreated patients without del(17p) or TP53 mutation, and outside summaries of the trial reported progression-free survival benefits over chemoimmunotherapy with a safety profile consistent with the known effects of the individual drugs. (ajmc.com) ### Where are the main caveats? The FDA label excludes patients with del(17p) or TP53 mutation, and that exclusion is central to the caution around broad use. Kittai told AJMC that questions remain about how well the regimen serves higher-risk subgroups and whether the benefit seen so far will prove durable over longer follow-up. Longer-term uncertainty is not a side issue in CLL. (fda.gov) A 2025 review in *Leukemia* said fixed-duration venetoclax-plus-BTK inhibitor strategies are promising but argued that differences among BTK inhibitors, follow-up length and subgroup outcomes still matter when comparing regimens. That review discussed AMPLIFY as important evidence for fixed-duration acalabrutinib plus venetoclax, while noting the trial population excluded del(17p) and TP53-mutated disease. (ajmc.com) ### What about safety? AMPLIFY investigators presented a post-hoc safety analysis showing that fixed-duration acalabrutinib-venetoclax combinations had manageable safety findings compared with chemoimmunotherapy. An International Workshop on CLL poster summary said more than 90% of patients considered high risk for tumor lysis syndrome at baseline moved to low or medium risk after two cycles of acalabrutinib lead-in before venetoclax. (nature.com) AJMC’s coverage emphasized that favorable safety does not erase the tradeoffs. Kittai’s caution was that tolerability, treatment duration and uncertainty after therapy ends all remain part of the counseling discussion, especially when other frontline targeted options remain available. ### How does this change the frontline CLL discussion? Frontline CLL decisions now include a more explicit choice between continuous disease control and a defined treatment stop. (iwcll.org) Kittai’s comments to AJMC place acalabrutinib plus venetoclax in the group of regimens that may fit patients who value time off treatment, but he did not present it as the default for every newly diagnosed patient. (ajmc.com) The next evidence will come from longer follow-up of AMPLIFY and from closer scrutiny of subgroup outcomes. Those data, rather than the initial approval alone, are likely to determine how widely fixed-duration acalabrutinib plus venetoclax is used in patients with higher-risk disease features and how firmly it holds its place in frontline CLL care. (ashpublications.org) (ajmc.com)